I was trying to post the picture of the Clinical Pipeline for CTIX.  It has Kevetrin entering Phase two trial for AML and a Phase 2/3 trial for Advanced Solid Tumors.  Is it to simplistic to say if they weren't already seeing efficacy the advanced solid tumors would also be a phase 2?  Showing a phase 2/3 would imply efficacy?   C'mon man, Granny needs a new pair of shoes.